Cure Alzheimer’s Fund Strengthens Leadership with New Board Members to Accelerate Fight Against Alzheimer’s

The Cure Alzheimer’s Fund, a pivotal nonprofit in the battle against Alzheimer’s disease, has recently announced the addition of Christine Villas-Boas and Brittany Bowlen to its Board of Directors. This development is poised to bring new energy and insights into the organization’s relentless pursuit of a cure for Alzheimer’s, a condition that impacts millions globally. The inclusion of Villas-Boas and Bowlen is not just a routine update; it represents a strategic infusion of talent and dedication aimed at accelerating the organization’s mission.

Henry McCance, the Board Chair and Co-Founder of Cure Alzheimer’s Fund, has voiced his optimism about the fresh perspectives and skills that Villas-Boas and Bowlen are expected to contribute. Villas-Boas’s profound background in finance and philanthropy, coupled with her personal ties to the cause due to her family’s encounter with Alzheimer’s, positions her as a passionate advocate for the organization’s objectives. Bowlen, on the other hand, brings to the table her remarkable leadership in strategy and community impact, aligning perfectly with the fund’s vision for a future free from Alzheimer’s.

Since its establishment in 2004, the Cure Alzheimer’s Fund has been a cornerstone in Alzheimer’s research, channeling more than $232 million into supporting over 300 top researchers. A distinctive feature of the organization is its commitment to ensuring that 100% of general donations go directly to research programs, a policy made possible by its Board of Directors and Trustees covering all overhead costs. This approach has not only maximized the impact of every dollar donated but has also earned the fund high accolades, including top ratings from Charity Navigator and a Platinum Seal of Transparency from Candid.

The appointment of Villas-Boas and Bowlen is a testament to the Cure Alzheimer’s Fund’s dedication to not just maintaining but enhancing its impact in the fight against Alzheimer’s. Their leadership and heartfelt commitment are anticipated to propel the organization forward, bringing hope to millions affected by this debilitating disease. As the fund continues to break new ground in Alzheimer’s research, the addition of these two dynamic leaders underscores the importance of collective effort and innovation in overcoming one of the most challenging health crises of our time.